AbbVie reported a Phase 3 win for lutikizumab, its IL-1α/IL-1β inhibitor, in hidradenitis suppurativa, but the results missed expectations and raised questions about competitive positioning. In the Intrepid trial, AbbVie enrolled 1,400 patients with moderate-to-severe hidradenitis suppurativa and evaluated weekly injections for 16 weeks. The primary endpoint showed 31.4% of patients treated with lutikizumab achieved at least a 75% reduction in inflamed bumps and abscesses versus 23.4% on placebo. AbbVie also reported that the drug met eight secondary endpoints, including improvements in skin pain and flare outcomes, and that the therapy was generally safe, with adverse event rates close to placebo. The key nuance for biotech is that primary efficacy performance was positive, yet the magnitude was not enough to satisfy investors focused on whether lutikizumab could outperform existing standards of care and differentiate meaningfully in commercial terms. The story notes that experts were cautious about the drug’s ability to compete given the topline. AbbVie’s next steps are framed around potential regulatory filing timing, with market participants watching whether additional analyses or endpoints can sharpen the value case.